Form 4: Labcorp Executive Mark S. Schroeder Reports Stock Transactions
SEC Form 4 Filing
Mark S. Schroeder, EVP, Pres Diagnostics & COO of Labcorp Holdings Inc., reports acquisition and disposal of common stock on March 27 and 28, 2025.
Summary
- Mark S. Schroeder, an executive at Labcorp, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On March 27, 2025, Schroeder acquired 4,840 shares of common stock related to a performance award.
- Also on March 27, 2025, 2,205 shares were disposed of to cover tax obligations at a price of $231.67.
- On March 28, 2025, Schroeder sold 2,635 shares at $231.67 per share under a pre-arranged 10b5-1 trading plan.
- Following these transactions, Schroeder directly owns 4,960.1426 shares of Labcorp common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are a mix of stock acquisition and disposal for tax purposes and pre-planned sales. There is no indication of unusual activity or cause for concern.
Positives
- The acquisition of shares indicates confidence in the company's performance, as the shares were awarded based on performance during the three-year period ended December 31, 2024.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. They are often scrutinized by investors to gauge management's sentiment about the company's prospects. Sales under 10b5-1 plans are generally less impactful as they are pre-arranged.
Comparison to Industry Standards
- Executive compensation structures, including performance-based awards, are standard practice among publicly traded companies like Labcorp.
- Companies such as Quest Diagnostics (DGX) and Bio-Rad Laboratories (BIO) also utilize similar compensation strategies to incentivize their executives.
- The use of 10b5-1 trading plans is a common method for executives to sell shares while avoiding accusations of insider trading; many executives at comparable companies use these plans.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on stakeholders as they are routine and do not indicate any fundamental change in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| February 11, 2022 | Date of performance award grant. |
| December 31, 2024 | End of the three-year performance period related to the performance award. |
| March 27, 2025 | Date of stock acquisition and tax obligation disposal. |
| March 28, 2025 | Date of stock sale under 10b5-1 plan. |
| March 31, 2025 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Labcorp, Schroeder, Executive Compensation, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.